This editorial refers to 'Development of significant tricuspid regurgitation over time and prognostic indications: new insights into natural history' † , by E.A. Prihadi et al., on page 3574.
The 20th century found little attention paid to tricuspid regurgitation (TR). Most TR is secondary to right ventricular (RV) pressure or volume overload and, as such, the reasoning was treat the primary cause and the TR will improve. There is of course merit to this concept. However, the 21st century brought new focus on TR for several reasons. First, the increased use of device leads that cross the tricuspid valve increased the incidence of both nuisance and more serious TR. Second, cardiac surgery performed in patients with TR due to leftside overloading valve lesions did not always improve TR following left-sided surgery. In fact, paradoxically, not only did TR fail to improve following surgery, it sometimes worsened. 1 Thus, the clinician was left with a patient with well-treated left heart disease only to have them suffer from right heart failure. The problem of postoperative TR was compounded by the fact that reoperation on such patients to treat residual TR often had a very high operative risk.
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Third, we came to realize that we had very few benchmarks to guide therapy. While several parameters are recognized 'triggers' for leftsided intervention, 4 almost none exist to guide TR therapy, leaving the clinician in a quandary about what to do and when to do it. Thus, in the surgical community, there is a broad difference of opinion regarding intraoperative management of secondary TR, ranging at one end of the spectrum where patients are aggressively treated with a dilated annulus even if TR is absent 5 to, at the other end, avoiding tricuspid repair in all but the most severe cases. 6 The management decision is made harder because, in some patients, TR improves following left-sided surgery, only to worsen later in time. [7] [8] [9] The only area of agreement is that tricuspid repair or replacement at the time of left-sided surgery reduces TR or prevents its worsening post-operatively. 10, 11 There is some evidence that TR treatment during leftsided surgery reduces post-operative heart failure, 12,13 but there is little proof that TR treatment improves long-term survival, albeit there have been no rigorous prospective survival trials to adequately examine the hypothesis.
The current study: what we learned
In this issue of the European Heart Journal, Prihadi et al. advance our knowledge about the progression of TR and some of the factors predicting that progression. 14 They started with patients who already had moderate or severe TR, and then looked backward to see if there had been previous echocardiograms when TR was mild or absent. They then categorized the rapidity of progression according to the time interval between when the TR was milder to when it had become more severe. The authors should be congratulated for personally reviewing the images, adding scientific muscle to the study. It seems that all too often, studies today are published from mining large administrative databases, presenting a large sample size but having questionable accuracy, since the actual images and the data accrued from them are not reviewed by the investigators. Defined by the way the study was performed, all 1000 patients had moderate or severe TR. Importantly, 25% of these patients progressed from less-severe TR within < 1.2 years. Not surprisingly but impressively, the biggest determinant of rapid progression was whether patients had no vs. mild TR initially. Only 40 patients with initially no TR were rapid progressors, and only 30% of patients with no TR initially progressed to moderate or severe TR throughout the entire study period. Other factors leading to rapid progression included age (average 68 years), female sex, device leads across the valve, reduced RV function, and annular enlargement. As the authors note, the study design does not permit us to know how many patients never progress nor can we guess at the bias introduced by whatever factors caused the clinicians to perform the repeated echocardiograms in the first place. However, what the study does tell us is that (i) some patients may progress very rapidly, especially if they have mild TR to begin with, and (ii) that rapid progressors are at increased risk for a poor outcome. What we cannot know, but what should invoke future study, is whether rapidly progressing TR is a target for therapy or simply a reporter of adverse pathology. If the rapid progression of TR itself is causing a poor outcome, it is a target for therapy. As such, patients with mild TR should be followed carefully, treating TR possibly with the range of less-invasive techniques currently on the horizon. If rapid progression is only a marker of trouble and not the cause, it will be helpful prognostically but will have less impact on patient management.
What we need to learn (perhaps a lesson from mitral regurgitation)
What we do not know is whether worsening TR occurs unpredictably (capriciously) or is due to other factors that predict outcome besides those learned in the present study. In primary mitral regurgitation (MR) for instance, we know that effective regurgitant orifice area, a falling ejection fraction, increasing end systolic dimension (volume), increasing pulmonary artery pressure, and increasing biomarkers portend a poor outcome, which is ameliorated by timely mechanical intervention. 4 We have much less knowledge about intervention in secondary MR, perhaps germane here since most TR is secondary. Some of these questions may be answered by a current CTSnet trial of concomitant mild to moderate TR repair in patients undergoing mitral surgery. In any case, we should develop additional benchmarks, based on RV performance and biology, that can help us time if and when TR should be addressed mechanically.
Conclusion
The medical management of secondary TR is straightforward: treat the underlying causes such as left ventricular failure and lung disease. Its surgical management is fraught because so few data are available to point the way. The study by Prihadi et al. adds to our knowledge base regarding the progression of TR and should make us more vigilant to its presence. However, we still have a lot to learn.
